Cover Image
市場調查報告書

肌肉骨骼疾病治療藥的全球市場:2016∼2020年

Global Musculoskeletal Disorders Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 369194
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
肌肉骨骼疾病治療藥的全球市場:2016∼2020年 Global Musculoskeletal Disorders Therapeutics Market 2016-2020
出版日期: 2016年08月31日 內容資訊: 英文 120 Pages
簡介

肌肉骨骼疾病,是影響身體的關節、肌肉、神經等的疼痛或損傷,有各種原因。根據症狀治療方法也不同,除了藥物之外有物理治療和作業療法等。全球肌肉骨骼疾病治療藥市場預計2016∼2020年以4.46%的年複合成長率擴大

本報告提供全球肌肉骨骼疾病治療藥市場相關調查,市場的各分子類型,各給藥途徑,各地區趨勢,今後的成長預測,以及加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 產品研發線

第6章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 肌肉骨骼疾病治療藥的全球市場:各疾病市場區隔

  • 類風濕性關節炎
  • 骨關節炎
  • 骨質疏鬆症
  • 乾癬性關節炎
  • 僵直性脊椎炎
  • 纖維肌痛

第8章 全球類風濕性關節炎治療藥市場

第9章 全球骨關節炎治療藥市場

第10章 全球骨質疏鬆症治療藥市場

第11章 全球僵直性脊椎炎劑市場

第12章 全球乾癬性關節炎治療藥市場

第13章 全球纖維肌痛治療藥市場

第14章 各分子類型市場區隔

  • 生技藥品
  • 小分子

第15章 各給藥途徑市場區隔

  • 非口服
  • 局部
  • 口服

第16章 各地區市場區隔

  • 各地區市場
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第17章 推動市場的要素

第18章 促進要素的影響

第19章 市場課題

第20章 促進要素與課題的影響

第21章 市場趨勢

第22章 供應商環境

第23章 主要供應商

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • Pfizer
  • F. Hoffmann-La Roche
  • Eli Lilly
  • 其他值得注意的供應商

第24章 附錄

第25章 關於Technavio

目錄
Product Code: IRTNTR10170

About Musculoskeletal Disorders

Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide range of causes, but usually occur depending on the age, lifestyle, and occupation of an individual. Symptoms usually range from recurrent pain, stiffness, and swellings. X-rays and other medical imaging procedures may diagnose the condition. The treatment mainly depends on the severity of the condition. Apart from the drugs, physical therapy, and occupational therapy are also used to manage the condition.

Technavio's analysts forecast the global musculoskeletal disorder therapeutics market to grow at a CAGR of 4.46% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global musculoskeletal disorder therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic arthritis, and fibromyalgia.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Musculoskeletal Disorder Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • Pfizer
  • F. Hoffmann-La Roche
  • Eli Lilly

Other Prominent Vendors

  • 3SBio
  • AB Sciences
  • AbGenomics International
  • Ablynx
  • Adheron
  • Akron Molecules AG
  • Alder BioPharmaceuticals
  • Amgen Astellas BioPharma K.K. in Japan
  • Ampio Pharmaceuticals
  • Antares Medical Services
  • Astellas
  • AstraZeneca
  • Baxter
  • Biocad
  • Bioiberica
  • Boehringer Ingelheim
  • Bone Therapeutics
  • Can-Fite BioPharma
  • Celgene
  • Celltrion
  • Cellular Biomedicine
  • Cerapedics
  • ChemoCentryx
  • Chugai Pharmaceutical
  • Coherus Biosciences
  • Daiichi Sankyo
  • Dong-A ST
  • Edding Pharm
  • Eisai
  • Epirus
  • Eupraxia Pharmaceuticals
  • Flexion Therapeutics
  • Galapagos NV
  • Gedeon Richter
  • Gilead Sciences
  • GlaxoSmithKline
  • Histogenics
  • IBSA Institut Biochimique
  • iCeutica
  • Iltoo Pharma
  • Incyte
  • Innovative Med Concepts
  • Iroko Pharmaceuticals
  • ISTO Technologies
  • KaloBios Pharmaceuticals
  • KAN Research Institute
  • Kang Stem Biotech
  • Kitov Pharmaceuticals
  • Lexicon Pharmaceuticals
  • LG Life Sciences
  • MEDIPOST
  • Medivir
  • Merck
  • Mereo
  • Mesoblast
  • MOCHIDA PHARMACEUTICAL
  • MorphoSys
  • Morphotek
  • Mycenax
  • Neomed Institute
  • Novartis
  • Omeros
  • OrthoTrophix
  • Osteologix
  • OxyPharma
  • PFEnex
  • Philogen
  • PhytoHealth
  • Plexxikon
  • PLx Pharma
  • Protalex
  • Proximagen
  • Radius Health
  • Regeneron Pharmaceuticals
  • Samsung Bioepis
  • Samumed
  • Sandoz
  • Sanofi
  • SantoSolve AS
  • Steminent Biotherapeutics
  • Stempeutics Research
  • Taiwan Liposome Company
  • Takeda
  • Tarsa Therapeutics
  • Techfields Pharma
  • Tetec AG
  • TheraMAB
  • TiGenix
  • TissueGene
  • Tonix Pharmaceuticals
  • Translational Biosciences
  • UCB
  • Vericel
  • Vertex Pharmaceuticals
  • Vitaeris
  • Winston Laboratories
  • Zosano Pharma

Market driver

  • Tentative approval of advanced drugs
  • For a full, detailed list, view our report

Market challenge

  • Growing preference toward surgeries
  • For a full, detailed list, view our report

Market trend

  • Ongoing active clinical trials for biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by disease type

  • Rheumatoid arthritis
  • Osteoarthritis
  • Osteoporosis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Fibromyalgia

PART 08: Global rheumatoid arthritis drugs market

  • Market overview

PART 09: Global osteoarthritis drugs market

  • Market overview

PART 10: Global osteoporosis drugs market

  • Market overview

PART 11: Global ankylosing spondylitis drugs market

  • Market overview

PART 12: Global psoriatic arthritis drugs market

  • Market overview

PART 13: Global fibromyalgia drugs market

  • Market overview

PART 14: Market segmentation by type of molecule

  • Biologics
  • Small molecules

PART 15: Market segmentation by route of administration

  • Parenteral
  • Topical
  • Oral

PART 16: Geographical segmentation

  • Global musculoskeletal disorder therapeutics market by geography 2015-2020
  • Musculoskeletal disorders therapeutics market in Americas
  • Musculoskeletal disorders therapeutics market in EMEA
  • Musculoskeletal disorders therapeutics market in APAC

PART 17: Market drivers

  • High growth potential of mAbs
  • Unmet needs of therapeutics
  • Tentative approval of advanced drugs
  • Technological advancements in medical imaging
  • Combination therapies

PART 18: Impact of drivers

PART 19: Market challenges

  • Non-adherence to treatment regimen
  • Growing preference toward surgeries
  • Multiple patent expiries

PART 20: Impact of drivers and challenges

PART 21: Market trends

  • Focus on regenerative medicines
  • Ongoing active clinical trials for biosimilars
  • Growing focus toward abuse-resistant novel drugs

PART 22: Vendor landscape

  • Competitive scenario

PART 23: Key vendor analysis

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • Pfizer
  • F. Hoffmann-La Roche
  • Eli Lilly
  • Other prominent vendors

PART 24: Appendix

  • List of abbreviations

PART 25: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key customer segments for musculoskeletal disorder therapeutics
  • Exhibit 03: Impact of biologics on various sectors
  • Exhibit 04: Pipeline portfolio: Global rheumatoid arthritis drugs market
  • Exhibit 05: Pipeline portfolio: Global osteoarthritis drugs market
  • Exhibit 06: Pipeline portfolio: Global osteoporosis drugs market
  • Exhibit 07: Pipeline portfolio: Global psoriatic arthritis drugs market
  • Exhibit 08: Pipeline portfolio: Global fibromyalgia drugs market
  • Exhibit 09: Pipeline portfolio: Global ankylosing spondylitis drugs market
  • Exhibit 10: Global musculoskeletal disorder therapeutics market 2015-2020 ($ billions)
  • Exhibit 11: Patient assistance programs offered by companies
  • Exhibit 12: CAM therapies for rheumatoid arthritis
  • Exhibit 13: Five forces analysis
  • Exhibit 14: Segmentation of global musculoskeletal disorder therapeutics market
  • Exhibit 15: Segmentation of global musculoskeletal disorder therapeutics market by revenue 2015
  • Exhibit 16: Opportunities in rheumatoid arthritis drugs industry
  • Exhibit 17: Global rheumatoid arthritis drugs market 2015-2020 ($ billions)
  • Exhibit 18: Unmet medical needs with current osteoarthritis treatments
  • Exhibit 19: Global osteoarthritis drugs market 2015-2020 ($ billions)
  • Exhibit 20: Global osteoporosis drugs market 2015-2020 ($ billions)
  • Exhibit 21: Global ankylosing spondylitis drugs market 2015-2020 ($ billions)
  • Exhibit 22: Global psoriatic arthritis drugs market 2015-2020 ($ billions)
  • Exhibit 23: Global fibromyalgia drugs market 2015-2020 ($ billions)
  • Exhibit 24: Segmentation of global musculoskeletal disorder therapeutics market by type of molecules 2015
  • Exhibit 25: Segmentation of global musculoskeletal disorder therapeutics market by ROA 2015
  • Exhibit 26: Global musculoskeletal disorder therapeutics market by geography 2015-2020
  • Exhibit 27: Global musculoskeletal disorder therapeutics market segmentation by geography 2015-2020 ($ billions)
  • Exhibit 28: Global share of musculoskeletal disorders therapeutics market by geography 2015
  • Exhibit 29: Global musculoskeletal disorder therapeutics market: Country analysis based on revenue and growth rate
  • Exhibit 30: Musculoskeletal disorders therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 31: Musculoskeletal disorders therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 32: Musculoskeletal disorders therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 33: Few of the late-stage mAbs under development for various musculoskeletal disorders
  • Exhibit 34: Impact of drivers
  • Exhibit 35: Approval and patent expiries of top selling biologics
  • Exhibit 36: Impact of drivers and challenges
  • Exhibit 37: Key vendors ranking 2015
  • Exhibit 38: Geographical presence of key vendors
  • Exhibit 39: Competitive scenario of global musculoskeletal disorder therapeutics market vendors 2015-2020
  • Exhibit 40: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
  • Exhibit 41: AbbVie: Geographical segmentation of Humira 2015
  • Exhibit 42: AbbVie: Metrics analysis
  • Exhibit 43: Key products in musculoskeletal disorders market with 2015 revenues
  • Exhibit 44: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
  • Exhibit 45: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
  • Exhibit 46: Johnson & Johnson: YoY revenue and growth rate of Stelara 2013-2015 ($ billions)
  • Exhibit 47: Johnson & Johnson: Metrics analysis
  • Exhibit 48: Amgen: YoY revenue and growth rate of Enbrel (US and Canada) 2013-2015 ($ billions)
  • Exhibit 49: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ billions)
  • Exhibit 50: Amgen: Geographical segmentation of Prolia 2015
  • Exhibit 51: Amgen: Metrics analysis
  • Exhibit 52: Key products in musculoskeletal disorders market with 2015 revenues
  • Exhibit 53: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
  • Exhibit 54: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
  • Exhibit 55: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions)
  • Exhibit 56: Pfizer: YoY revenue and growth rate of Xeljanz 2013-2015 ($ millions)
  • Exhibit 57: Pfizer: Metrics analysis
  • Exhibit 58: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan 2013-2015 ($ billions)
  • Exhibit 59: F. Hoffmann-La Roche: Geographical segmentation of MabThera/Rituxan by revenue 2015
  • Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
  • Exhibit 61: F. Hoffmann-La Roche: Geographical segmentation of Actemra/RoActemra by revenue 2015
  • Exhibit 62: F. Hoffmann-La Roche: Metrics analysis
  • Exhibit 63: Eli Lilly: YoY revenue and growth rate of Cymbalta 2013-2015 ($ billions)
  • Exhibit 64: Eli Lilly: YoY revenue and growth rate of Evista 2013-2015 ($ billions)
  • Exhibit 65: Eli Lilly: Geographical segmentation of Evista 2015
  • Exhibit 66: Eli Lilly: YoY revenue and growth rate of Forteo 2013-2015 ($ billions)
  • Exhibit 67: Eli Lilly: Geographical segmentation of Forteo 2015
  • Exhibit 68: Eli Lilly: Metrics analysis
Back to Top